Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala(Tampere University), Kim N.(Asian Institute of Technology), Kevin Beja(University of British Columbia), Katherine Sunderland(BC Cancer Agency), Joanna Vergidis(BC Cancer Agency), Sinja Taavitsainen(Tampere University of Applied Sciences), Daniel Khalaf(BC Cancer Agency), Alexander W. Wyatt(University of British Columbia), Gillian Vandekerkhove(University of British Columbia), Conrad D. Oja(BC Cancer Agency), Martin Gleave(University of British Columbia), Matti Nykter(University of Liverpool), Arun Azad(Peter MacCallum Cancer Centre), Christian Kollmannsberger(BC Cancer Agency), Bernhard J. Eigl(BC Cancer Agency), Muhammad Zulfiqar(BC Cancer Agency), Evan W. Warner(Guardant (United States)), Daygen L. Finch(Interior Health)
Cited by 520
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Antisense therapy for cancer
|Nature reviews. Cancer|2005|399